Evaluation of electrocardiographic parameters in patients with hearing loss genotyped for the connexin 26 gene (GJB2) mutations / Avaliação dos parâmetros eletrocardiográficos em pacientes com perda auditiva genotipada para mutações do gene conexina 26 (GJB2)

Abstract Introduction: Several studies have associated congenital sensorineural hearing loss in children with prolongation of the cardiac parameter QTc. The cause of this association is unknown. At the same time, mutations in GJB2, which encodes connexin 26, are the most common cause of congenital hearing impairment. Objective: To compare electrocardiographic parameters (PR interval, QRS complex, and QTc interval) in patients with hearing loss who were tested for mutations in GJB2 and GJB6 to investigate whether these mutations affect electrical activity of the heart. Methods: 346 patients (176 males, 170 females) with sensorineural hearing loss of 30 dB HL or more, aged 21.8 ± 19.9 years (including 147 children <14 years), underwent both genetic study for GJB2 and GJB6 mutations and electrocardiography. Results: Mutations in GJB2, including homozygotes and heterozygotes, were found in 112 (32%) patients. There were no significant differences in ECG parameters between groups of patients with and without mutations in GJB2. No differences were observed either in men (mean PR with mutation: 155 ± 16.6 vs. 153.6 ± 30.1 without; QRS: 99.9 ± 9.9 vs. 101.1 ± 15.4; QTc: 414.9 ± 29.9 vs. 412.4 ± 25.7) or women (mean PR with: 148.7 ± 21 vs. 143.8 ± 22.8 without; QRS: 94.8 ± 7.6 vs. 92.9 ± 9.6; QTc: 416.8 ± 20.6 vs. 424.9 ± 22.8). In similar fashion, we did we find any significant differences between groups of children with and without GJB2 mutations (mean PR with: 126.3 ± 19.6 vs. 127 ± 19.7 without; QRS: 80.7 ± 9.5 vs. 79.4 ± 11.6; QTc: 419.7 ± 23.5 vs. 419.8 ± 24.8). Conclusion: No association was found between the presence of GJB2 mutations encoding connexin 26 in patients with hearing loss and their ECG parameters (PR, QRS, QTc).

Resumo Introdução: Vários estudos têm associado a perda auditiva neurossensorial congênita em crianças ao prolongamento do parâmetro cardíaco QTc. A causa dessa associação é desconhecida. Ao mesmo tempo, as mutações no GJB2, que codifica a conexina 26, são a causa mais comum de deficiência auditiva congênita. Objetivo: Comparar parâmetros eletrocardiográficos (intervalo PR, complexos QRS e intervalo QTc) em pacientes com perda auditiva que foram testados para mutações no GJB2 e GJB6 para investigar se essas mutações afetam a atividade elétrica do coração. Método: Foram submetidos a estudo genético para mutações de GJB2 e GJB6 e eletrocardiograma 346 pacientes (176 homens, 170 mulheres) com perda auditiva neurossensorial de 30 dB ou mais, com média de 21,8 ± 19,9 anos (incluindo 147 crianças <14 anos). Resultados: Mutações no GJB2, inclusive homozigóticos e heterozigóticos, foram encontradas em 112 (32%) pacientes. Não houve diferenças significativas nos parâmetros de ECG entre grupos de pacientes com e sem mutações no GJB2. Não foram observadas diferenças em homens (PR médio com mutação: 155 ± 16,6 vs. 153,6 ± 30,1 sem mutação; QRS: 99,9 ± 9,9 vs. 101,1 ± 15,4; QTc: 414,9 ± 29,9 vs. 412,4 ± 25,7) nem em mulheres (PR médio com: 148,7 ± 21 vs. 143,8 ± 22,8, sem; QRS: 94,8 ± 7,6 vs. 92,9 ± 9,6; QTc: 416,8 ± 20,6 vs. 424,9 ± 22,8). Da mesma forma, encontramos diferenças significativas entre os grupos de crianças com e sem mutações de GJB2 (PR médio com: 126,3 ± 19,6 vs. 127 ± 19,7, sem; QRS: 80,7 ± 9,5 vs. 79,4 ± 11,6; QTc: 419,7 ± 23,5 vs. 419,8 ± 24,8). Conclusão: Não foi encontrada associação entre a presença de mutações de GJB2 que codificam conexina 26 em pacientes com perda auditiva e seus parâmetros de ECG (PR, QRS, QTc).

Arritmias genéticas: como investigar e como tratar? / Inherited arrhythmias: how to investigate and how to treat?

As arritmias hereditárias são responsáveis por uma proporção significante de mortes cardíacas súbitas em indivíduos jovens aparentemente saudáveis. As canalopatias, como síndrome de Brugada, síndrome do QT longo/curto e taquicardia ventricular polimórfica catecolaminérgica, contribuem com essa incidência e não são marcadas por anomalias estruturais. A cardiomiopatia genética, como cardiomiopatia arritmogênica doventrículo direito e cardiomiopatia hipertrófica, também são causas de morte súbita por arritmia. Novos consensos têm sido publicados para orientar melhor as ferramentas dediagnóstico, os escores de estratificação e o tratamento. Os testes genéticos têm papel importante no diagnóstico, na estratificação de risco e no tratamento de pacientes e de suas famílias. Os avanços da genética molecular nas duas últimas décadas revelaram a base genética subjacente da doença, e podem levar a tratamentos mais personalizados...

Inherited arrhythmias account for a significant proportion of sudden cardiac deaths in apparently healthy and young individuals. Ion channelopathies such as Brugada syndrome, long/short QT syndrome and catecholaminergic polymorphic ventricular tachycardiacontribute to this incidence and are marked by no structural abnormalities. Genetic cardiomyopathy such as Right Ventricular Arrhythmogenic Cardiomyopathy and HypertrophicCardiomyopathy are also causes of arrhythmogenic sudden death. New consensuses are published to better guide the diagnostic tools, stratification scores and treatment. Genetic testing plays somehow an important role in the diagnosis, risk-stratification and treatment of patients and family members. Molecular genetic advances in the last 2 decades have revealed the underlying genetic basis and these may lead to a personalized medicine...

Síndrome de Andersen-Tawil / Andersen-Tawil Syndrome

A síndrome de Andersen-Tawil é uma condição rara composta por arritmias ventriculares, paralisia periódica e dimorfismo. É uma doença de canal iônico cardíaco, possui herança de forma autossômica dominante e é classificada como tipo 7 da síndrome do QT longo congênito. A síndrome de Andersen-Tawil é a única canalopatia que une a excitabilidade dos músculos cardíaco e esquelético. Os pacientes podem ser assintomáticos ou minimamente sintomáticos, apesar da elevada carga de arritmia com ectopia ventricular frequente e taquicardia ventricular bidirecional. No entanto, continuam a ser pacientes com risco de arritmias potencialmente fatais, incluindo torsades de pointes e fibrilação ventricular, embora com menor frequência que as observadas em outras síndromes de arritmia genética. Nesta revisão a doença foi abordada sob o ponto de vista dos diagnósticos clínico e molecular, com ênfase nas manifestações cardíacas...

Andersen-Tawil syndrome is a rare condition consisting of ventricular arrhythmias, periodic paralysis, and dysmorphic features. It is a cardiac ion channel disease, with autosomal dominant inheritance and is classifiedas type 7 of the congenital long QT syndromes. Andersen-Tawil syndrome is a unique channelopathy which linkscardiac and skeletal muscle excitability. Patients may be asymptomatic, or minimally symptomatic despite a higharrhythmia burden with frequent ventricular ectopy and bidirectional ventricular tachycardia. However, patients remain at risk for life-threatening arrhythmias, including torsades de pointes and ventricular fibrillation, although less frequently than observed in other genetic arrhythmia syndromes. In this review we address the disease from the point of view of clinical and molecular diagnosis with emphasis on cardiac manifestations...

Sudden Cardiac Arrest during Anesthesia in a 30-Month-Old Boy with Syndactyly: A Case of Genetically Proven Timothy Syndrome

Timothy syndrome, long QT syndrome type 8, is highly malignant with ventricular tachyarrhythmia. A 30-month-old boy had sudden cardiac arrest during anesthesia induction before plastic surgery for bilateral cutaneous syndactyly. After successful resuscitation, prolonged QT interval (QTc, 0.58-0.60 sec) and T-wave alternans were found in his electrocardiogram. Starting beta-blocker to prevent further tachycardia and collapse event, then there were no more arrhythmic events. The genes KCNQ1, KCNH2, KCNE1 and 2, and SCN5A were negative for long QT syndrome. The mutation p.Gly406Arg was confirmed in CACNA1C, which maintains L-type calcium channel depolarization in the heart and other systems.

Síndrome de QT corto / Short QT syndrome

El síndrome de QT corto es una canalopatía hereditaria caracterizada por un anormal acortamiento del intervalo QT (IQT), por un riesgo incrementado para el desarrollo de fibrilación auricular y/o arritmias ventriculares malignas y por la ausencia de cardiopatía estructural. Es una enfermedad heterogénea y se han identificado mutaciones en los genes codificadores de los canales de potasio y de calcio. Un incremento en las corrientes neta de salida de potasio o una disminución en al entrada de calcio favorecen el acortamiento heterogéneo de la repolarización ventricular. La marcada abreviación de la longitud de onda del circuito es un factor arritmogénico adicional. El curso clínico oscila desde formas asintomáticas hasta fibrilación auricular paroxística o permanente, síncope, arritmias ventriculares y muerte súbita. El electrocardiograma muestra IQT 220-360 ms, ondas T altas y puntiagudas, prolongación del intervalo pico-final de la onda T e IQT rígido. Es poco frecuente, pero importante por el riesgo elevado de muerte súbita, que en ocasiones puede ser el debut. Puede presentarse solapado al síndrome de Brugada y a la repolarización precoz. El diagnóstico precisa excluir las causas secundarias que acortan el IQT y la no identificación de una mutación no lo excluye. La estimulación eléctrica programada tiene pobre valor diagnóstico y pronóstico. En los sujetos con muerte súbita abortada o con arritmias ventriculares con compromiso hemodinámica, el desfibrilador es la terapéutica de elección. La quinidina es una opción terapéutica alternativa

The short QT syndrome is an inherited channelopathy characterized by an abnormal shortening of the QT interval (QTI), an increased risk of developing atrial fibrillation and/or malignant ventricular arrhythmias, and the absence of structural heart disease. It is a heterogeneous disease and mutations have been identified in the genes encoding potassium and calcium channels. An increase in potassium net efflux or a decrease in calcium influx facilitate the heterogeneous shortening of ventricular repolarization. A marked shortening of the wavelength of the circuit is an additional arrhythmogenic factor. The clinical course ranges from asymptomatic forms to paroxysmal or permanent atrial fibrillation, syncope, ventricular arrhythmias and sudden death. The ECG shows QTI 220-360 ms, high and sharp T waves, prolongation of the final peak interval of the T wave, and QTI drive. It is a rare disease whose importance lies in the high risk of sudden death, which may sometimes be its debut. It may overlap Brugada syndrome and early repolarization. Diagnosis requires excluding secondary causes of QTI shortening. Failure to identify a mutation does not exclude it. Programmed electrical stimulation has a low diagnostic and prognostic value. Defibrillation is the therapy of choice for patients with aborted sudden death or ventricular arrhythmias with hemodynamic compromise. Quinidine is an alternative therapeutic option

Investigação de variantes gênicas de canais iônicos em pacientes com síndrome do QT longo / Investigation of ion channel gene variants in patients with long QT syndrome / Investigación de variantes génicas de canales iónicos en pacientes con síndrome del QT largo

FUNDAMENTO: A síndrome do QT longo (SQTL) é uma síndrome arrítmica herdada com aumento do intervalo QT e risco de morte súbita. Mutações nos genes KCNQ1, KCNH2 e SCN5A respondem por 90 por cento dos casos com genótipo determinado, e a genotipagem é informativa para aconselhamento genético e melhor manejo da doença. OBJETIVO: Investigação molecular e análise computacional de variantes gênicas de KCNQ1, KCNH2 e SCN5A associadas à SQTL em famílias portadoras da doença. MÉTODOS: As regiões codificantes dos genes KCNQ1, KCNH2 e SCN5A de pacientes com SQTL e familiares foram sequenciadas e analisadas utilizando o software Geneious ProTM. RESULTADOS: Foram investigadas duas famílias com critérios clínicos para SQTL. A probanda da Família A apresentava QTC = 562 ms, Escore de Schwartz = 5,5. A genotipagem identificou a mutação G1714A no gene KCNH2. Foi observado QTC = 521 ± 42 ms nos familiares portadores da mutação contra QTC = 391 ± 21 ms de não portadores. A probanda da Família B apresentava QTc = 551 ms, Escore de Schwartz = 5. A genotipagem identificou a mutação G1600T, no mesmo gene. A análise dos familiares revelou QTC = 497 ± 42 ms nos portadores da mutação, contra QTC = 404 ± 29 ms nos não portadores. CONCLUSÃO: Foram encontradas duas variantes gênicas previamente associadas à SQTL em duas famílias com diagnóstico clínico de SQTL. Em todos os familiares portadores das mutações foi observado o prolongamento do intervalo QT. Foi desenvolvida uma estratégia para identificação de variantes dos genes KCNQ1, KCNH2 e SCN5A, possibilitando o treinamento de pessoal técnico para futura aplicação na rotina diagnóstica.

BACKGROUND: The long QT syndrome (LQTS) is an inherited arrhythmia syndrome with increased QT interval and risk of sudden death. Mutations in genes KCNQ1, KCNH2 and SCN5A account for 90 percent of cases with genotype determined, and genotyping is informative for genetic counseling and better disease management. OBJECTIVE: Molecular investigation and computational analysis of gene variants of KCNQ1, KCNH2 and SCN5A associated with LQTS, in families with the disease. METHODS: The coding regions of genes KCNQ1, KCNH2 and SCN5A in patients with LQTS and their family members were sequenced and analyzed using Geneious ProTM software. RESULTS: Two families with clinical criteria for LQTS were investigated. The proband of Family A had QTC = 562 ms, Schwartz Score = 5.5. The genotyping identified the G1714A mutation in the KCNH2 gene. QTC = 521 ± 42 ms was observed in family members carrying the mutation against QTC = 391 ± 21 ms for non-carriers. The proband of Family B had QTc = 551 ms, Schwartz Score = 5.5. The genotyping identified the G1600T mutation, in the same gene. The analysis of family members revealed QTC = 497 ± 42 ms in mutation carriers, compared with QTC = 404 ± 29 ms in non-carriers. CONCLUSION: Two gene variants previously associated with LQTS were found in two families clinically diagnosed with LQTS. The prolongation of the QT interval was observed in all family members carrying the mutations. A strategy was developed to identify variants of genes KCNQ1, KCNH2 and SCN5A, making it possible to train technical staff for future application to diagnosis routine.

FUNDAMENTO: El síndrome del QT largo (SQTL) es un síndrome arrítmico heredado con aumento del intervalo QT y riesgo de muerte súbita. Mutaciones en los genes KCNQ1, KCNH2 y SCN5A responden por 90 por ciento de los casos con genotipo determinado, y el genotipaje es informativo para aconsejamiento genético y mejor manejo de la enfermedad. OBJETIVO: Investigación molecular y análisis computacional de variantes génicas de KCNQ1, KCNH2 y SCN5A asociadas a la SQTL en familias portadoras de la enfermedad. MÉTODOS: Las regiones codificantes de los genes KCNQ1, KCNH2 y SCN5A de pacientes con SQTL y familiares fueron secuenciadas y analizadas utilizando el software Geneious Pro®. RESULTADOS: Fueron investigadas dos familias con criterios clínicos para SQTL. La probanda de la Familia A presentaba QT C = 562 ms, Escore de Schwartz = 5,5. El genotipaje identificó la mutación G1714A en el gen KCNH2. Fue observado QT C = 521 ± 42 ms en los familiares portadores de la mutación contra QT C = 391 ± 21 ms de no portadores. La probanda de la Familia B presentaba QT C = 551 ms, Escore de Schwartz = 5. El genotipaje identificó la mutación G1600T, en el mismo gen. El análisis de los familiares reveló QT C = 497 ± 42 ms en los portadores de la mutación, contra QT C = 404 ± 29 ms en los no portadores. CONCLUSIÓN: Fueron encontradas dos variantes génicas previamente asociadas a la SQTL en dos familias con diagnóstico clínico de SQTL. En todos los familiares portadores de las mutaciones fue observada la prolongación del intervalo QT. Fue desarrollada una estrategia para identificación de variantes de los genes KCNQ1, KCNH2 y SCN5A, posibilitando el entrenamiento de personal técnico para futura aplicación en la rutina diagnóstica.

Postmortem genetic testing in sudden cardiac death due to ion channelopathies / 法医学杂志

Sudden cardiac death accounts for majority of deaths in human. Evident cardiac lesions that may explain the cause of death can be detected in comprehensive postmortem investigation in most sudden cardiac death. However, no cardiac morphological abnormality is found in a considerable number of cases although the death is highly suspected from cardiac anomaly. With the advances in the modern molecular biology techniques, it has been discovered that many of these sudden deaths are caused by congenital ion channelopathies in myocardial cell, i.e., Brugada syndrome, long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome, etc. This article presents the molecular genetics, electrocardiographic abnormalities, clinical manifestations, and mechanisms leading to sudden cardiac death with emphasis on the role of postmortem genetic testing in certification of cause of death. It may provide helpful information in investigating sudden cardiac death due to ion channelopathies in medico-legal practice.

Nuevas perspectivas en el síndrome de QT largo / New perspectives in long QT syndrome

Long QT Syndrome (LQTS) is a cardiac channelopathy characterized by prolonged ventricular repolarization and increased risk to sudden death secondary to ventricular dysrrhythmias. Was the first cardiac channelopathy described and is probably the best understood. After a decade of the sentinel identification of ion channel mutation in LQTS, genotype-phenotype correlations have been developed along with important improvement in risk stratification and genetic guided-treatment. Genetic screening has shown that LQTS is more frequent than expected and interestingly, ethnic specific polymorphism conferring increased susceptibility to drug induced QT prolongation and torsades de pointes have been identified. A better understanding of ventricular arrhythmias as an adverse effect of ion channel binding drugs, allow the development of more safety formulas and better control of this public health problem. Progress in understanding the molecular basis of LQTS has been remarkable; eight different genes have been identified, however still 25% of patients remain genotype-negative. This article is an overview of the main LQTS knowledge developed during the last years.

El síndrome de QT largo (SQTL) es una canalopatía que genera grave alteración en la repolarización ventricular predispone a arritmias malignas y muerte súbita. Fue la primera canalopatía arritmogénica descrita y quizá la mejor entendida hasta ahora. Transcurrida ya más de una década de la identificación de la primera mutación asociada al SQTL, se ha hecho evidente que este trastorno es mucho más frecuente de lo que inicialmente se pensaba; los avances en el conocimiento de la fisiopatología molecular de esta enfermedad han permitido hacer una correlación genotipo-fenotipo, optimizando el tratamiento y permitiendo estratificar el riesgo en forma precisa. Se ha logrado entender con mayor detalle los efectos adversos de distintas drogas que interactúan con los canales iónicos, permitiendo así generar fármacos más seguros y, en su defecto, monitorizar de cerca aquellos que a pesar de tener este efecto adverso, es necesaria su administración. Los avances son importantes pero no todo está dicho, 25% de los casos no tienen mutaciones en los genes descritos hasta la fecha, por lo que el SQTL continúa siendo motivo de investigación. El presente artículo constituye un resumen de los principales conceptos desarrollados en los últimos diez años que han sido cruciales en el manejo de esta enfermedad.

Intervalo QT prolongado inducido por fármacos desde el punto de vista de un farmacólogo / Drug induced QT interval prolongation: a pharmacologist's point of view

El síndrome QT largo adquirido es provocado principalmente por el uso de fármacos que prolongan la repolarización ventricular. Si bien es conocido que la mayoría de los antiarrítmicos presentan esta propiedad, también es compartida por alrededor de 100 drogas no antiarrítmicas. Pese a que el riesgo de proarritmia con la mayoría de estos fármacos es bajo, la incidencia de esta reacción adversa es importante debido a su amplio uso. Por otro lado, existen numerosos factores predisponentes que incrementan el riesgo de torsade de pointes, como la predisposición genética, el sexo femenino, la hipopotasemia y la disfunción cardíaca. Además, la mayoría de los casos de torsade de pointes inducido por fármacos se han detectado en pacientes tratados con más de un fármaco que presenta esta propiedad o bajo tratamiento con un inhibidor enzimático. De acuerdo con esto, la mayoría de los casos de síndrome QT largo adquirido se podrían evitar mediante una selección correcta del paciente, así como con un control adecuado de la terapia farmacológica. Por lo tanto, es de interés que los distintos profesionales de la salud estén actualizados en esta problemática y puedan aplicar medidas para evitar o reducir la incidencia de esta proarritmia.

Clinical characteristics of 5 Chinese LQTS families and phenotype-genotype correlation / 华中科技大学学报（医学）（英德文版）

In order to assess the clinical manifestations and electrocardiogram (ECG) characteristics of Chinese long QT syndrome (LQTS) patients and describe the phenotype-genotype correlation, the subjects from 5 congenital LQTS families underwent clinical detailed examination including resting body surface ECG. QT interval and transmural dispersion of repolarization (TDR) were manually measured. Five families were genotyped by linkage analysis (polymerase chain reacting-short tandem repeat, PCR-STR). The phenotype-genotype correlation was analyzed. Four families were LQT2, 1 family was LQT3. Twenty-eight gene carriers were (14 males and 14 females) identified from 5 families. The mean QTc and TDRc were 0.56 +/- 0.04 s (range 0.42 to 0.63) and 0.16 +/- 0.04 s (range 0.09 to 0.24) respectively. 35.7% (10/28) had normal to borderline QTc (< or = 0.460 s). There was significant difference in QTc and TDRc between the patients with symptomatic LQTS and those with asymptomatic LQTS, and there was significant difference in TDRc between the asymptomatic patients and normal people also. A history of cardiac events was present in 50% (14/28), including 9 with syncope, 2 with sudden death (SD) and occurred in the absence of beta-blocker. Three SDs occurred prior to the diagnosis of LQTS and had no ECG record. Two out of 5 SDs (40%) occurred as the first symptom. Typical LQT2 T wave pattern were found in 40% (6/15) of all affected members. The appearing-normal T wave was found in one LQT3 family. Low penetrance of QTc and symptoms resulted in diagnostic challenge. ECG patterns and repolarization parameters may be used to predict the genotype in most families. Genetic test is very important for identification of gene carriers.

El sindrome de QT prolongado explicado a partir de las alteraciones del potencial de accion por canalopatias / Long QT syndrome and action potential for channelopathy

Las arritmias cardiacas constituyen un problema de alto impacto en cuanto a la morbimortalidad en la población general y la economía de los sistemas de salud a nivel mundial. Éstas se pueden explicar en parte por la disfunción molecular de los canales de transporte iónicos que se expresan en las membranas de las células cardiacas, cuya integridad depende no sólo del substrato genético del cual se derivan, sino también de factores postraduccionales celulares y de factores externos. Los defectos en los canales iónicos del cardiomiocito (heredados o adquiridos) que produzcan corrientes sostenidas despolarizantes o que reduzcan las corrientes repolarizantes y, por tanto, que prolonguen la duración del potencial de acción, se manifiestan en el trazado electrocardiográfico como una prolongación del intervalo QT y constituyen un substrato arritmogénico. A partir de estos conceptos han surgido nuevas teorías para explicar, desde el punto de vista molecular, eventos como la muerte súbita en adultos y en lactantes, la fibrilación ventricular idiopática y la arritmia de tipo Torsades de Pointes. La investigación de (as canalopatías permitirá abordar el problema de una manera más racional